Ad
related to: pros and cons of immunosuppression technology journal medicine guidelines- About Regeneron
Industry-Leading Biotechnology
Reinventing Drug Discovery
- Genetic Research
Speeding Drug Discovery
Learn about the RGC
- Science & Technology
See Regeneron's New Technology
Turning Science into Medicine
- Antibodies at Work
End-to-End Research & Development
See Regeneron's Approved Medicines
- About Regeneron
Search results
Results From The WOW.Com Content Network
Immunosuppression is a reduction of the activation or efficacy of the immune system. Some portions of the immune system itself have immunosuppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system.Immunotherapy is designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
The explanation for this is that while "biologic" or "biopharmaceutical" refers to the chemical composition of medications which might be used to treat a range of medical conditions, when the term "biologic" became popular, many biologic medications available provided immunosuppression.
Immunosuppressive drugs, also known as immunosuppressive agents, immunosuppressants and antirejection medications, are drugs that inhibit or prevent the activity of the immune system. Classification [ edit ]
For medications, the term immunosuppression generally refers to both beneficial and potential adverse effects of decreasing the function of the immune system, while the term immunodeficiency generally refers solely to the adverse effect of increased risk for infection. Many specific diseases directly or indirectly cause immunosuppression.
Leflunomide, sold under the brand name Arava among others, is an immunosuppressive disease-modifying antirheumatic drug , [8] used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis. It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate dehydrogenase. [9] Bottle of Leflunomide (Arava) and tablet
The ICMJE recommendations (full title, "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals") are a set of guidelines produced by the International Committee of Medical Journal Editors for standardising the ethics, preparation and formatting of manuscripts submitted to biomedical journals for publication. [1]
It was approved for medical use in the United States in 1995 following the discovery of its immunosuppressive properties in the 1990s. [13] [14] It is available as a generic medication. [16] In 2022, it was the 227th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [17] [18]